BioSpace News Archive

GE HealthCare announced it received a grant from the Bill & Melinda Gates Foundation for more than $44 million to create user-friendly, artificial intelligence -assisted ultrasound imaging auto-assessment tools.

Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will participate in the upcoming Gilmartin Group Emerging Growth Company Showcase. Management is scheduled to present on Thursday, September 21st at 9:00 a.m. Pacific Time/ 12:00 p.m. Eastern Time.

PharmaEssentia Corporation announced the company is included in the FTSE Global Equity Index Series, FTSE All-World Index, FTSE global All-Cap and total-Cap Indices, and the FTSE Global Mid Cap Index.

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that XACDURO® (sulbactam for injection; durlobactam for injection) is now available in the United States for patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Virpax ® Pharmaceuticals, Inc. today announced that it has formed a new wholly-owned subsidiary, Novvae™ Pharmaceuticals, Inc. (Novvae), which has been established to focus exclusively on advancing Virpax’s OTC pipeline.

Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com ). Enzolytics, Inc. announces today that it has executed the binding business combination agreement for the sale of Biogenysis, Inc.and Virogentics Inc. the operating subsidiaries of Enzolytics Inc., to Sagaliam Acquisition Corp (NASDAQ: SAGA) in a transaction valued at $450,000,000.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced the initiation of a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against an undisclosed bacterial pathogen.

LinKinVax, a clinical-stage biotechnology company focusing on innovative protein-based vaccines, and Gustave Roussy, the leading cancer centre in Europe ranked third Best Cancer Hospital in the world, announced the treatment at Gustave Roussy of the first patient in a Phase I/IIa clinical study with CD40HVac, a new therapeutic vaccine candidate for HPV-positive oropharyngeal cancer.

Cantex Pharmaceuticals, Inc. and Lenox Hill Hospital’s Department of Neurological Surgery announced the initiation of a Phase 2 study to assess the safety and effectiveness of azeliragon in combination with radiation therapy as a treatment for newly diagnosed unmethylated glioblastoma.

Inogen, Inc. announced it has completed the acquisition of Physio-Assist SAS, expanding the company’s innovative respiratory portfolio.